GlassScriptPhysician profile
Palak Shroff
NPI 1487094090
$4,314.75
in general payments reported to CMS, 2019-2025
43 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $116 · 2021: $190 · 2022: $891 · 2023: $629 · 2024: $779 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.99 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $449.95 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $401.17 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $372.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $350.53 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $290.18 | 2022-2025 | |
| Amgen INC. | $274.91 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $261.45 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $185.91 | 2022-2025 | |
| Abbott Laboratories | $184.97 | 2020-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $173.42 | 2025 | Inspire |
| Lilly USA, LLC | $171.99 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $140.85 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.86 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| E.R. Squibb & Sons, L.L.C. | $93.81 | 2022-2025 | Eliquis, Opdivo, Camzyos |
| Dynavax Technologies Corporation | $60.11 | 2024-2025 | Heplisav-B |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palak Shroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.